Program
Tamsulosin
Also written as “tamsulosin hydrochloride”, “Tamsulosin (0.4 mg/j)” and “tamsulosin”.
Its studies are mostly in Prostatic Hyperplasia · Lower Urinary Tract Symptoms · Erectile Dysfunction · Urologic Diseases · Urinary Bladder, Neurogenic, led by 15 companies.
Drug pageTamsulosin: every studyMany companies study it; this page follows only the 56 they lead. All 155 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheimits history only | 140 open or running | phase 4since Sep 18, 2014 | Jun 19, 2006 | none ahead |
| Astellas Pharmaits history only | 100 open or running | phase 4since Mar 17, 2016 | Jul 25, 2007 | none ahead |
| GlaxoSmithKlineits history only | 90 open or running | phase 4since Feb 10, 2011 | Aug 24, 2004 | none ahead |
| Hanmi Pharmaceuticalits history only | 50 open or running | phase 3since Feb 23, 2015 | Sep 4, 2014 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 30 open or running | phase 3since Sep 2, 2015 | Sep 15, 2014 | none ahead |
| Menarini Groupits history only | 33 open or running | phase 1since Jul 22, 2025 | Jul 22, 2025 | none ahead |
| GL Pharm Techits history only | 20 open or running | phase 3since Nov 11, 2014 | Feb 24, 2014 | none ahead |
| Jeil Pharmaceuticalits history only | 20 open or running | phase 3since Nov 21, 2016 | Jul 1, 2014 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 1since Jun 22, 2010 | Jun 22, 2010 | none ahead |
| adiumits history only | 10 open or running | no phasesince Jul 7, 2026 | Jul 7, 2026 | none ahead |
| ascension-healthits history only | 10 open or running | phase 4since Nov 5, 2016 | Nov 5, 2016 | none ahead |
| Dexa Medica Groupits history only | 10 open or running | phase 1since Aug 14, 2024 | Aug 14, 2024 | none ahead |
| getz-pharmaits history only | 10 open or running | phase 4since Jul 7, 2023 | Jul 7, 2023 | none ahead |
| IlDong Pharmaceuticalits history only | 10 open or running | phase 3since Jul 22, 2016 | Jul 22, 2016 | none ahead |
| neotract-incits history only | 11 open or running | phase 4since Jul 9, 2021 | Jul 9, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 41 studies since Aug 24, 2004.
- Oct 1, 2015Phase 3 study in Urological ManifestationsBoehringer Ingelheim · NCT02573311 · 1,117 enrolled · United States
- Dec 16, 2015Phase 1 study in Prostatic HyperplasiaAstellas Pharma · NCT02634489 · 46 enrolled · Netherlands
- Jan 29, 2016Phase 1 study in Erectile DysfunctionHanmi Pharmaceutical · NCT02715401 · 36 enrolled
- Feb 24, 2016Phase 1 study in Erectile DysfunctionHanmi Pharmaceutical · NCT02712411 · 30 enrolled · Korea, Republic of
- Mar 17, 2016Phase 4 study in Lower Urinary Tract SymptomsAstellas Pharma · NCT02715024 · 52 enrolled · Taiwan
- Jul 22, 2016IlDong Pharmaceutical’s first study: phase 3 study in Prostatic HyperplasiaNew to IlDong PharmaceuticalIlDong Pharmaceutical · NCT02862483 · 330 enrolled · Korea, Republic of
- Nov 5, 2016ascension-health’s first study: phase 4 study in Postoperative Urinary RetentionNew to ascension-healthascension-health · NCT02958878 · 210 enrolled
- Nov 21, 2016Phase 3 study in Lower Urinary Tract SymptomsJeil Pharmaceutical · NCT02972268 · 780 enrolled · Korea, Republic of
- Jul 9, 2021neotract-inc’s first study: phase 4 study in BPHNew to neotract-incneotract-inc · NCT04987892 · 250 planned · United States
- Jul 7, 2023getz-pharma’s first study: phase 4 study in Ureteric Stone of Lower Third of UreterNew to getz-pharmagetz-pharma · NCT05977647 · 240 enrolled · Pakistan
- Aug 14, 2024Dexa Medica Group’s first study: phase 1 study in HealthyNew to Dexa Medica GroupDexa Medica Group · NCT06558032 · 28 enrolled · Indonesia
- Jul 22, 2025Menarini Group’s first study: phase 1 study in Healthy VolunteersNew to Menarini GroupMenarini Group · NCT07091669 · 46 enrolled · Armenia
- Aug 21, 20252 phase 1 studiesMenarini Group · NCT07146711, NCT07156916
- Jul 7, 2026adium’s first study: no phase study in BioequivalenceNew to adiumadium · NCT07698288 · 66 enrolled · Mexico
TargetBeta
“Adrenergic receptor alpha-1 antagonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Oxymetazolinerule | AbbVie | phase 4 | 20 |
| Phentolaminerule | opus-genetics-inc | phase 4 | 18 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
| Midodrinerule | Takeda | phase 4 | 10 |
| Prazosinrule | Pfizer | phase 3 | 4 |
Studies
All 56 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07698288Bioequivalence · Mexico | – | Completed | adium | Apr 16, 2026 | 66 |
| NCT07156916Healthy Volunteer Male Subjects · Armenia | 1 | Recruiting | Menarini Group | Mar 1, 2026 | 46 |
| NCT07146711Healthy Adult Males Volunteers · Armenia | 1 | Active, not recruiting | Menarini Group | Oct 1, 2025 | 33 |
| NCT07091669Healthy Volunteers · Armenia | 1 | Active, not recruiting | Menarini Group | Aug 1, 2025 | 46 |
| NCT06558032Healthy · Indonesia | 1 | Completed | Dexa Medica Group | Dec 16, 2023 | 28 |
| NCT05977647Ureteric Stone of Lower Third of Ureter · Pakistan | 4 | Completed | getz-pharma | May 30, 2025 | 240 |
| NCT04987892BPH · United States | 4 | Recruiting | neotract-inc | May 2025 | 250 |
| NCT02972268Lower Urinary Tract Symptoms · Korea, Republic of | 3 | Completed | Jeil Pharmaceutical | Nov 2, 2017 | 780 |
| NCT02958878Postoperative Urinary Retention | 4 | Completed | ascension-health | Nov 30, 2018 | 210 |
| NCT02862483Prostatic Hyperplasia · Korea, Republic of | 3 | UNKNOWN | IlDong Pharmaceutical | Mar 2017 | 330 |
| NCT02715024Lower Urinary Tract Symptoms · Taiwan | 4 | Completed | Astellas Pharma | Apr 2011 | 52 |
| NCT02712411Erectile Dysfunction · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Aug 2015 | 30 |
| NCT02715401Erectile Dysfunction | 1 | Completed | Hanmi Pharmaceutical | Nov 2015 | 36 |
| NCT02634489Prostatic Hyperplasia · Netherlands | 1 | Completed | Astellas Pharma | Jul 2009 | 46 |
| NCT02573311Urological Manifestations · United States | 3 | Completed | Boehringer Ingelheim | Aug 1, 2016 | 1,117 |
| NCT03246880Prostatic Hyperplasia · Korea, Republic of | 3 | Completed | Chong Kun Dang Pharmaceutical | Apr 2016 | 455 |
| NCT02529800Healthy | 1 | Completed | Hanmi Pharmaceutical | Oct 2015 | 24 |
| NCT02417844Prostatic Hyperplasia | 1 | Completed | Boehringer Ingelheim | May 2015 | 34 |
| NCT02390882Prostatic Hyperplasia · Korea, Republic of | 3 | Completed | Hanmi Pharmaceutical | May 2015 | 494 |
| NCT02303769Prostatic Hyperplasia · Korea, Republic of | 3 | Completed | GL Pharm Tech | May 2015 | 309 |
| NCT02266537Healthy | 1 | Completed | Boehringer Ingelheim | Feb 2006 | 97 |
| NCT02266524Urination Disorders | 1 | Completed | Boehringer Ingelheim | Apr 2005 | 48 |
| NCT02266511Healthy | 1 | Completed | Boehringer Ingelheim | Sep 1999 | 30 |
| NCT02264184Healthy | 1 | Completed | Boehringer Ingelheim | Dec 2008 | 24 |
| NCT02244294Prostatic Hyperplasia | 2 | Completed | Boehringer Ingelheim | Jun 2005 | 176 |
| NCT02244281Lower Urinary Tract Symptoms | 2 | Completed | Boehringer Ingelheim | Nov 2003 | 74 |
| NCT02244255Prostatic Hyperplasia | 4 | Completed | Boehringer Ingelheim | Jun 2000 | 1,993 |
| NCT02244242Prostatic Hyperplasia | 4 | Completed | Boehringer Ingelheim | Aug 1999 | 493 |
| NCT02244229Prostatic Hyperplasia | 4 | Completed | Boehringer Ingelheim | Nov 2000 | 403 |
| NCT02247518Healthy · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Oct 2014 | 16 |
| NCT02247505Healty Male Volunteers · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Oct 2014 | 29 |
| NCT02239484Erectile Dysfunction · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Sep 2014 | 30 |
| NCT02180997Prostatic Hyperplasia · Korea, Republic of | 1 | Completed | Jeil Pharmaceutical | Mar 2015 | 36 |
| NCT02169713Healthy Subjects · Germany | 1 | Completed | Astellas Pharma | Aug 2014 | 20 |
| NCT02138773Healthy · China | 1 | Completed | Astellas Pharma | Jul 2014 | 80 |
| NCT02072213Healthy · Korea, Republic of | 1 | Completed | GL Pharm Tech | Jan 2014 | 36 |
| NCT02058576Urologic Diseases · United Kingdom | 1 | Completed | GlaxoSmithKline | Jan 2, 2015 | 77 |
| NCT02052713Urologic Diseases · United Kingdom | 1 | Completed | GlaxoSmithKline | Dec 29, 2014 | 78 |
| NCT02058368Prostatic Hyperplasia · China, Japan, Korea, Republic of and more | 3 | Completed | GlaxoSmithKline | Mar 3, 2017 | 607 |
| NCT01957189Prostatic Hyperplasia · China | 1 | Completed | GlaxoSmithKline | Jan 22, 2014 | 24 |
| NCT01953887EC905 · United Kingdom | 1 | Completed | Astellas Pharma | Jul 2010 | 30 |
| NCT01777269Prostatic Hyperplasia · Australia, France, Germany and more | 4 | Completed | GlaxoSmithKline | Apr 5, 2016 | 489 |
| NCT01726270Lower Urinary Tract Symptoms · United States | 2 | Completed | Boehringer Ingelheim | Mar 2013 | 689 |
| NCT01657851Prostatic Hyperplasia · Russian Federation | 1 | Completed | GlaxoSmithKline | Dec 5, 2012 | 35 |
| NCT01673490Prostatic Hyperplasia · Vietnam | 4 | Terminated | GlaxoSmithKline | Mar 20, 2015 | 59 |
| NCT01489696Cardiovascular · United Kingdom | 1 | Completed | Astellas Pharma | Feb 2011 | 48 |
| NCT01294592Prostatic Hyperplasia · France, Germany, Greece and more | 4 | Completed | GlaxoSmithKline | Oct 17, 2013 | 742 |
| NCT01149746Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Dec 2004 | 32 |
| NCT01149733Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Nov 2004 | 32 |
| NCT01021332Lower Urinary Tract Symptoms · Austria, Belarus, Belgium and more | 3 | Completed | Astellas Pharma | Dec 14, 2011 | 1,067 |
| NCT01018511Prostatic Hyperplasia · Austria, Belarus, Belgium and more | 3 | Completed | Astellas Pharma | Mar 1, 2011 | 1,334 |
| NCT00796614Urinary Bladder, Neurogenic · United States, Belgium, Brazil and more | 3 | Completed | Boehringer Ingelheim | Feb 2009 | 231 |
| NCT00510406Lower Urinary Tract Symptoms · Austria, Czech Republic, Denmark and more | 2 | Completed | Astellas Pharma | Sep 2007 | 919 |
| NCT00507455Lower Urinary Tract Symptoms · United States, Belgium, Czech Republic and more | 2 | Completed | Astellas Pharma | Aug 2008 | 222 |
| NCT00340704Urinary Bladder, Neurogenic · United States, Belgium, Brazil and more | 2 | Completed | Boehringer Ingelheim | Jun 2009 | 143 |
| NCT00090103Prostatic Hyperplasia · United States, Argentina, Belgium and more | 3 | Completed | GlaxoSmithKline | Apr 2009 | 4,844 |
How it is read
Names in the registry
- “Tamsulosin”, 12 entries
- “tamsulosin hydrochloride”, 6 entries
- “Tamsulosin (0.4 mg/j)”, 5 entries
- “tamsulosin”, 4 entries
- “HIP1402”, 3 entries
Conditions, from the studies’ own filings
- Prostatic Hyperplasia, 22 studies
- Lower Urinary Tract Symptoms, 6 studies
- Erectile Dysfunction, 3 studies
- Urologic Diseases, 2 studies
- Urinary Bladder, Neurogenic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.